Business Wire

ZHEJIANG-DAHUA-TECH

10.5.2021 15:47:05 CEST | Business Wire | Press release

Share
Dahua Technology Unveils Upgraded WizMind to Enhance AI Experience

Dahua Technology, a world-leading video-centric smart IoT solution and service provider, has recently released its upgraded WizMind series, offering a comprehensive project-oriented product portfolio and flexible AI solutions that focus on human, vehicle, object and thermal technology to empower vertical markets with enhanced AI experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005414/en/

Human-based Applications

Adopting topnotch AI chip and algorithms, the upgraded human-based WizMind solution includes privacy protection 2.0, face recognition 2.0, human video metadata 2.0 and other advanced AI performance to enable timely responses to incidents while providing accurate customer flow, crowd density, target direction, etc. to assist in further business analysis. Privacy Protection 2.0 offers additional occlusion options (irregular polygons, mosaics, and colored blocks) and supports code exporting based on specified targets, ensuring privacy safety of people and places.

Vehicle-based Applications

The upgraded vehicle-based WizMind solution integrates ANPR, parking space management, vehicle metadata 2.0 and other technologies to serve multiple vehicle-based scenes. It can accurately detect and display parking status and number of available parking spaces, and supports overlaying a variety of information on the vehicle’s snapshot. Moreover, a dual-PTZ system can even capture detailed images of vehicles under occlusion.

Object-based Applications

As a brand new feature of the upgraded WizMind, the Dahua object monitoring technology utilizes deep-learning algorithms to detect up to six kinds of objects. It can effectively filter out false alarms caused by interference and provide customers with accurate alarm information. Through the linkage alarm connected to the administrator, it can help passenger find missing items, or detect a blockage at the fire exit, thus reducing property loss and increasing safety level.

Thermal Imaging Applications

Dahua thermal imaging technology adopts the industry-leading thermal imaging sensor and excellent image processing algorithm to deliver 24/7 long-range surveillance performance. Its abnormal behavior detection, high-accurate alarms and other AI-enabled intelligent analysis functions make it ideal for airports, border security, infrastructures, fire prevention, etc.

WizMind Ecosystem

Dahua WizMind is compatible with a variety of third-party platforms. It provides sufficient API to allow integration with Dahua partners’ systems. Dahua DHOP supports third-party access to WizMind IPC and thermal cameras, enabling customization of flexible camera functions.

Boasting accurate, reliable and comprehensive AI-powered technical highlights, the upgraded WizMind series brings high-end customized solutions and convenience to users with project needs in traffic management, building, retail, energy and many other industries.

*Product launch date might vary depending on countries.

Link:

ClickThru

Social Media:

https://www.facebook.com/DahuaHQ

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye